ATE199013T1 - N-(4-SUBSTITUTED BENZYL)-2-AMINOLACTAM DERIVATIVES - Google Patents

N-(4-SUBSTITUTED BENZYL)-2-AMINOLACTAM DERIVATIVES

Info

Publication number
ATE199013T1
ATE199013T1 AT96925667T AT96925667T ATE199013T1 AT E199013 T1 ATE199013 T1 AT E199013T1 AT 96925667 T AT96925667 T AT 96925667T AT 96925667 T AT96925667 T AT 96925667T AT E199013 T1 ATE199013 T1 AT E199013T1
Authority
AT
Austria
Prior art keywords
pct
substituted benzyl
sec
aminolactam
derivatives
Prior art date
Application number
AT96925667T
Other languages
German (de)
Inventor
Paolo Pevarello
Raffaella Amici
Mario Varasi
Roberto Maj
Patricia Salvati
Original Assignee
Newron Pharm Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Newron Pharm Spa filed Critical Newron Pharm Spa
Application granted granted Critical
Publication of ATE199013T1 publication Critical patent/ATE199013T1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24—Oxygen or sulfur atoms
    • C07D207/26—2-Pyrrolidones
    • C07D207/273—2-Pyrrolidones with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/06—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D205/08—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with one oxygen atom directly attached in position 2, e.g. beta-lactams
    • C07D205/085—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with one oxygen atom directly attached in position 2, e.g. beta-lactams with a nitrogen atom directly attached in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D211/72—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D211/74—Oxygen atoms
    • C07D211/76—Oxygen atoms attached in position 2 or 6

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

PCT No. PCT/EP96/02962 Sec. 371 Date Jan. 8, 1998 Sec. 102(e) Date Jan. 8, 1998 PCT Filed Jul. 5, 1996 PCT Pub. No. WO97/05111 PCT Pub. Date Feb. 13, 1997The present invention relates to novel N-(4-substituted-benzyl)-2-aminolactams as therapeutic agents, pharmaceutical compositions and a process of preparation.
AT96925667T 1995-07-27 1996-07-05 N-(4-SUBSTITUTED BENZYL)-2-AMINOLACTAM DERIVATIVES ATE199013T1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9515411.8A GB9515411D0 (en) 1995-07-27 1995-07-27 N-(4-substituted-benzyl)-2-aminolactam derivatives
PCT/EP1996/002962 WO1997005111A1 (en) 1995-07-27 1996-07-05 N-(4-substituted-benzyl)-2-aminolactam derivatives

Publications (1)

Publication Number Publication Date
ATE199013T1 true ATE199013T1 (en) 2001-02-15

Family

ID=10778351

Family Applications (1)

Application Number Title Priority Date Filing Date
AT96925667T ATE199013T1 (en) 1995-07-27 1996-07-05 N-(4-SUBSTITUTED BENZYL)-2-AMINOLACTAM DERIVATIVES

Country Status (13)

Country Link
US (1) US5912242A (en)
EP (1) EP0842152B1 (en)
JP (1) JP3939755B2 (en)
AT (1) ATE199013T1 (en)
AU (1) AU6611696A (en)
BR (1) BR9609847A (en)
CA (1) CA2226886C (en)
DE (1) DE69611728T2 (en)
ES (1) ES2154830T3 (en)
GB (1) GB9515411D0 (en)
IL (1) IL122706A0 (en)
WO (1) WO1997005111A1 (en)
ZA (1) ZA965997B (en)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9727523D0 (en) 1997-12-31 1998-02-25 Pharmacia & Upjohn Spa Alpha-aminoamide derivatives useful as analgesic agents
ES2258980T3 (en) 1999-08-16 2006-09-16 Revaax Pharmaceuticals Llc PHARMACEUTICAL COMPOSITIONS THAT INCLUDE CLAVULANIC ACID OR DERIVATIVES OF THE SAME FOR THE TREATMENT OF BEHAVIOR DISORDERS.
US6489319B2 (en) * 1999-08-16 2002-12-03 Revaax Pharmaceuticals, Llc Neurotherapeutic use of carboxypeptidase inhibitors
US6426342B2 (en) * 1999-08-16 2002-07-30 Revaax Pharmaceuticals, Llc Use of β-lactamase inhibitors as neuroprotectants
IL160523A0 (en) 2001-09-03 2004-07-25 Newron Pharm Spa PHARMACEUTICAL COMPOSITION COMPRISING GABAPENTIN OR AN ANALOGUE THEREOF AND AN alpha-AMINOAMIDE AND ITS ANALGESIC USE
EP1438956A1 (en) 2003-01-16 2004-07-21 Newron Pharmaceuticals S.p.A. Alpha-aminoamide derivatives useful as antimigraine agents
US7163937B2 (en) 2003-08-21 2007-01-16 Bristol-Myers Squibb Company Cyclic derivatives as modulators of chemokine receptor activity
EP1524267A1 (en) 2003-10-15 2005-04-20 Newron Pharmaceuticals S.p.A. Substituted benzylaminoalkylene heterocycles
EP1533298A1 (en) * 2003-11-21 2005-05-25 Newron Pharmaceuticals S.p.A. 3-aminopyrrolidone derivatives
EP1588704A1 (en) 2004-04-22 2005-10-26 Newron Pharmaceuticals S.p.A. Alpha-aminoamide derivatives useful in the treatment of restless legs syndrome and addictive disorders
EP1870097A1 (en) 2006-06-15 2007-12-26 Newron Pharmaceuticals S.p.A. Alpha-aminoamide derivatives useful in the treatment of cognitive disorders
US7671062B2 (en) 2006-07-28 2010-03-02 Bristol-Myers Squibb Company Modulators of chemokine receptor activity, crystalline forms and process
US7687508B2 (en) 2006-07-28 2010-03-30 Bristol-Myers Squibb Company Cyclic derivatives as modulators of chemokine receptor activity
US7629351B2 (en) 2006-07-28 2009-12-08 Bristol-Myers Squibb Company N-((1R,2S,5R)-5-(tert-butylamino)-2-((S)-2-oxo-3-(6-(trifluoromethyl)quinazolin-4-ylamino) pyrrolidin-1-yl)cyclohexyl)acetamide and other modulators of chemokine receptor activity, crystalline forms and process
BRPI1013901A2 (en) * 2009-04-29 2019-09-24 Rexahn Pharmaceuticals Inc clavulanate formulation for neuroprotection and treatment of neurodegenerative disorders
US8383812B2 (en) 2009-10-13 2013-02-26 Bristol-Myers Squibb Company N-((1R,2S,5R)-5-(tert-butylamino)-2-((S)-3-(7-tert-butylpyrazolo[1,5-A][1,3,5]triazin-4-ylamino)-2-oxopyrrolidin-1-yl)cyclohexyl)acetamide, a dual modulator of chemokine receptor activity, crystalline forms and processes

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU518986B2 (en) * 1977-10-11 1981-10-29 Takeda Chemical Industries Ltd. Lactams
US4719207A (en) * 1984-06-25 1988-01-12 Yamanouchi Pharmaceutical Co., Ltd. CNS active substituted azetidinone compounds
GB8823605D0 (en) * 1988-10-07 1988-11-16 Merck Sharp & Dohme Therapeutic agents

Also Published As

Publication number Publication date
DE69611728T2 (en) 2001-05-10
ZA965997B (en) 1997-01-31
EP0842152B1 (en) 2001-01-31
DE69611728D1 (en) 2001-03-08
EP0842152A1 (en) 1998-05-20
US5912242A (en) 1999-06-15
AU6611696A (en) 1997-02-26
BR9609847A (en) 1999-03-09
WO1997005111A1 (en) 1997-02-13
CA2226886A1 (en) 1997-02-13
JP3939755B2 (en) 2007-07-04
IL122706A0 (en) 1998-08-16
GB9515411D0 (en) 1995-09-27
ES2154830T3 (en) 2001-04-16
CA2226886C (en) 2007-01-30
JPH11509848A (en) 1999-08-31

Similar Documents

Publication Publication Date Title
ATE199013T1 (en) N-(4-SUBSTITUTED BENZYL)-2-AMINOLACTAM DERIVATIVES
NO306346B1 (en) N-substituted azabicycloalkane derivatives, their use and pharmaceutical preparation
NO963850D0 (en) Heterocyclic compounds, their preparation and use
BR9611175B1 (en) pharmaceutical compounds and compositions.
NO963053D0 (en) Cosmetic or pharmaceutical preparations containing mangiferin or derivatives thereof
PT958296E (en) HETEROCYCLIC COMPOUNDS PROCESS FOR THEIR PREPARATION PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND ITS UTILIZATION IN THE TREATMENT OF RELATED DIABETES AND DISEASES
FR2743562B1 (en) N- (ARYLSULFONYL) AMINO ACID DERIVATIVES, THEIR PREPARATION, THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
MXPA02001340A (en) Novel 1,4-benzodiazepine compounds and derivatives thereof.
FR2712591B1 (en) New arylpiperazines derived from indole, their preparation and their therapeutic use.
FI972434A0 (en) Lamotrigine-containing pharmaceutical composition
DK0810991T3 (en) 1-Aryl-2-acylamino-ethane compounds and their use as neurokinin, especially neurokinin-1 antagonists
ATE233246T1 (en) HYDANTOIN DERIVATIVES AS INTERMEDIATE PRODUCTS FOR PHARMACEUTICAL ACTIVE INGREDIENTS
DK0891341T3 (en) 1,3,4-Oxadiazine derivatives and their use as pesticides
NO306400B1 (en) N-Substituted Azabicycloheptane Derivatives, Their Use and Pharmaceutical Preparation
DK0775143T3 (en) 3-substituted 3H-2,3-benzodiazepine derivatives, their preparation and use as drugs
BR9610175A (en) Compound preparation process of the pharmaceutical composition and use of the compound
PL323305A1 (en) Applications of allyl amines
DK0805817T3 (en) Thiol derivatives with metallopeptidase inhibitory activity
RU95102147A (en) 1-[2-(1h-inden-3-yl)ethyl]-4-(napht-1-yl)preparazine derivatives, process for preparation thereof, and drug and pharmaceutical composition containing said derivatives, and pharmaceutical composition
DK0815109T3 (en) Process for the preparation of esters of anhydroecgonine
TR200402685T4 (en) Cyclobutta-indole carboxamide derivatives acting on the central nervous system, their preparation methods and pharmaceutical compositions containing them.
ZA955052B (en) Pyrrolidine derivatives their preparation and compositions containing them
IT1277736B1 (en) TIOLIC DERIVATIVES FOR METALLOPEPTIDASE INHIBITIVE ACTIVITY
CA2241788A1 (en) Novel n-(arylsulphonyl)amino acid derivatives, their preparation process and pharmaceutical compositions containing them

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties